General Information of Drug (ID: DMEDLXJ)

Drug Name
ORBOFIBAN Drug Info
Synonyms
Orbofiban; UNII-FGJ53JS7PT; 163250-90-6; FGJ53JS7PT; CHEMBL64706; SC-57099B; Orbofiban [INN]; AC1L435J; SCHEMBL7854981; DTXSID20167543; ZINC3951736; BDBM50092109; AKOS022181223; AJ-47472; ethyl 3-[[(3S)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate; 3-{(S)-3-[1-(4-Carbamimidoyl-phenyl)-2-oxo-pyrrolidin-3-yl]-ureido}-propionic acid ethyl ester; beta-Alanine, N-((((3S)-1-(4-(aminoiminomethyl)phenyl)-2-oxo-3- pyrrolidinyl)amino)carbonyl)-, ethyl ester
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Discontinued in Phase 3 [1]
Cardiovascular disease BA00-BE2Z Discontinued in Phase 3 [2]
Cross-matching ID
PubChem CID
178080
CAS Number
CAS 163250-90-6
TTD Drug ID
DMEDLXJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [4]
Eptifibatide DMQXTJS Acute cardiac ischemic events BA40.Z Approved [5]
Tirofiban DMQG17S Acute coronary syndrome BA41 Approved [6]
Abciximab DMJO6GV Acute disease Approved [6]
DMP-444 DMO7BQS Coronary artery disease BA80 Phase 3 [7]
99mTc-rBitistatin DMFAMNH Pulmonary embolism JB42 Phase 1/2 [8]
AjvW2 DM6PN4H Thrombosis DB61-GB90 Phase 1 [9]
SDZ-GPI-562 DMU9ZGN Thrombosis DB61-GB90 Phase 1 [10]
RGD-891 DMVJMF1 Thrombosis DB61-GB90 Phase 1 [11]
Lefradafiban DMKZVLH Angina pectoris BA40 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) TT38RM1 ITA2B_HUMAN; ITB3_HUMAN Modulator [3]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007819)
2 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
3 Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001 May;21(3):211-26.
4 Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998 Nov 1;92(9):3268-76.
5 Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. Clin Nucl Med. 2003 Jun;28(6):480-4.
8 Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans. Nucl Med Biol. 2007 Oct;34(7):855-63.
9 Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
10 Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost. 1999;25 Suppl 1:67-75.
11 Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56.
12 Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50.